Inogen

INGN · NASDAQ

$6.69+$0.14 (+2.14%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.55

INGN analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $12.24 (+83.0% upside)

Low: $12.12
Now: $6.69
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

INGN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Freedom Broker	Apr 7, 2026	Initiates	Buy	$12.00	45%

The case for and against

Updated Dec 7, 2025

Bull case

Inogen Inc. is strategically positioning itself for growth by enhancing synergies across various sales channels, revitalizing its direct-to-consumer approach, and strengthening business-to-business relationships, thereby expanding its market reach. The partnership with Yuwell for entry into the Chinese COPD market presents substantial long-term growth opportunities, as this market is approximately ten times larger than that of the United States. Additionally, the projected growth of portable oxygen concentrators (POCs) to account for 58% of the market within the next five years indicates a favorable trend that could significantly benefit Inogen's revenue prospects.

Bear case

Inogen Inc has faced significant challenges due to an oversized sales force that led to unprofitable operations, despite prior revenue growth. The company reported a 17% decline in B2B sales and a 28% decline in DTC sales in 2023, indicating a severe downturn in its sales channels. Additionally, the shift from higher-paying Medicare to lower-reimbursing private insurance and an increasing number of capped patients is further exacerbating the revenue decline, contributing to a negative outlook for the company's financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.